Linagliptin for use in the treatment of albuminuria and kidney related diseases
Summary
The European Patent Office published patent application EP3685839A1 for Boehringer Ingelheim International GmbH, covering Linagliptin for use in treating albuminuria and kidney-related diseases. The patent application was published on April 1, 2026 with inventors Klein, von Eynatten, and Mark. The patent covers the pharmaceutical compound A61K 31/522 and related formulations.
What changed
The EPO published patent application EP3685839A1 for Linagliptin (a DPP-4 inhibitor) specifically claiming use in treating albuminuria and kidney-related diseases. The patent designation covers 36 European states including major pharmaceutical markets (DE, FR, GB, IT, ES, NL). The publication includes claims under multiple IPC classifications relating to heterocyclic compounds and therapeutic compositions.
Pharmaceutical companies developing or marketing diabetes medications or kidney disease treatments should conduct freedom-to-operate analyses. Generic drug manufacturers and biosimilar developers should review the specific albuminuria indications to assess potential patent clearance strategies. Healthcare investors and licensing professionals should note this patent extends Boehringer Ingelheim's Linagliptin (Trajenta/Tradjenta) franchise into nephrology applications.
What to do next
- Monitor freedom-to-operate implications for competing DPP-4 inhibitors
- Review patent claims for potential licensing opportunities in nephrology
- Update IP portfolio tracking systems with new EPO publication
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
LINAGLIPTIN FOR USE IN THE TREATMENT OF ALBUMINURIA AND KIDNEY RELATED DISEASES
Publication EP3685839A1 Kind: A1 Apr 01, 2026
Applicants
Boehringer Ingelheim International GmbH
Inventors
KLEIN, Thomas, VON EYNATTEN, Maximilian, MARK, Michael
IPC Classifications
A61K 31/522 20060101AFI20200623BHEP A61P 13/12 20060101ALI20200623BHEP A61K 31/401 20060101ALI20200623BHEP A61K 31/4184 20060101ALI20200623BHEP A61K 31/155 20060101ALI20200623BHEP A61K 45/06 20060101ALI20200623BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.